Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Lie Yao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109526022. Sources: OpenAlex.

Their work

Papers
18 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 5 papers · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 18

  1. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  2. Label-Free Histology and Evaluation of Human Pancreatic Cancer with Coherent Nonlinear Optical Microscopy. Co-author DOI 10.1021/acs.analchem.1c03861↗
  3. WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41416-020-0929-0↗
  4. LyP-1-fMWNTs enhanced targeted delivery of MBD1siRNA to pancreatic cancer cells. Co-author DOI 10.1111/jcmm.14864↗
  5. Partial pancreatic tail preserving subtotal pancreatectomy for pancreatic cancer: Improving glycemic control and quality of life without compromising oncologic… First author DOI 10.4240/wjgs.v12.i12.491↗
  6. Blood-based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Pancreatic Cancer and its Value to Guide Clinical Treatment. Co-author DOI 10.7150/jca.43087↗
  7. High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients. First author DOI 10.1016/j.ejso.2018.09.020↗
  8. The roles of ID-1 in human pancreatic ductal adenocarcinoma and the therapeutic effects of 2-methoxyestradiol. Co-author DOI 10.1093/carcin/bgy035↗
  9. Genome-Wide Analysis Identified a Number of Dysregulated Long Noncoding RNA (lncRNA) in Human Pancreatic Ductal Adenocarcinoma. First author DOI 10.1177/1533034617748429↗
  10. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-018-6727-8↗
  11. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. Co-author DOI 10.2147/ijn.s166769↗
  12. Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer. Co-author DOI 10.3892/ol.2018.8041↗
  13. Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein invo… Co-author DOI 10.18632/oncotarget.20847↗
  14. Application of Deuteporfin in the Metastatic Lymph Node Mapping of Pancreatic Cancer: An in vivo Study. First author DOI 10.1111/php.12574↗
  15. Circulating tumor cells in pancreatic cancer patients: efficacy in diagnosis and value in prognosis. First author PMID 27755967↗
  16. How to improve the efficacy of endoscopic ultrasound-guided celiac plexus neurolysis in pain management in patients with pancreatic cancer: analysis in a singl… Co-author DOI 10.1097/sle.0000000000000032↗
  17. MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1. Co-author DOI 10.4161/cbt.29706↗
  18. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer. Co-author DOI 10.3892/or.2013.2516↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Deliang Fu · 16 shared papers, 2013–2024 · strength 1.42
  2. Chen Jin · 11 shared papers, 2013–2020 · strength 0.90
  3. Zhibo Xie · 4 shared papers, 2016–2020 · strength 0.41
  4. Di Yang · 6 shared papers, 2013–2020 · strength 0.41
  5. Jichun Gu · 4 shared papers, 2017–2020 · strength 0.35
  6. Yongjian Jiang · 5 shared papers, 2013–2020 · strength 0.34
  7. Yifan Zhang · 3 shared papers, 2017–2020 · strength 0.33
  8. Hang He · 5 shared papers, 2013–2020 · strength 0.32
  9. Yishen Mao · 3 shared papers, 2018–2020 · strength 0.32
  10. Ji Li · 4 shared papers, 2013–2020 · strength 0.28
  11. Feng Yang · 4 shared papers, 2013–2018 · strength 0.23
  12. Wenquan Wang · 2 shared papers, 2018–2024 · strength 0.22
  13. Liang Liu · 2 shared papers, 2018–2024 · strength 0.22
  14. Quanjun Lin · 2 shared papers, 2018–2020 · strength 0.22
  15. Jie Fan · 2 shared papers, 2018–2021 · strength 0.21
  16. Ji Li · 3 shared papers, 2014–2020 · strength 0.21
  17. Hengchao Li · 2 shared papers, 2020 · strength 0.20
  18. Zhongyi Guo · 2 shared papers, 2018 · strength 0.17
  19. Sijie Hao · 3 shared papers, 2013–2018 · strength 0.16
  20. Xuefeng Xu · 1 shared paper, 2024 · strength 0.16
  21. Yaolin Xu · 1 shared paper, 2024 · strength 0.16
  22. Yuan Ji · 1 shared paper, 2024 · strength 0.16
  23. Yefei Rong · 1 shared paper, 2024 · strength 0.16
  24. Xi Guo · 1 shared paper, 2024 · strength 0.16
  25. Lili Wu · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.